GT Biopharma (GTBP) Current Deferred Revenue (2018 - 2019)

GT Biopharma (GTBP) posted quarterly Current Deferred Revenue of $8000.0 for Q3 2019, little changed quarter-over-quarter from $8000.0 in Q2 2019.

GT Biopharma (GTBP) Current Deferred Revenue (2018 - 2019) Analysis & Trends

GT Biopharma (GTBP) has reported Current Deferred Revenue for 2 consecutive years, with $8000.0 the latest figure, recorded in Q3 2019.

In Q3 2019, Current Deferred Revenue changed N/A year-over-year to $8000.0; the TTM figure through Sep 2019 stood at $8000.0 (changed N/A YoY), while the FY2018 annual figure was $8000.0, changed N/A from the prior year.
Current Deferred Revenue held at $8000.0 in Q3 2019 per GTBP's latest filing, from $8000.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $8000.0 in Q4 2018 and bottomed at $8000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	GT Biopharma	8.64 Mn	8.64 Mn	-

Download Data